VFY Shares Vitrafy Life Sciences Limited
ACCUMULATE ASX · ASXClinical and regulatory progress could unlock commercial partnerships and improve investor sentiment.
Future value: $5.07 (+110.18%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Expected regulatory and clinical milestone catalysts
- ▾Below 50-day MA (-30.56%)
- ▸~110% upside to price target
Is VFY a buy right now?
Trend: VFY is trading below the 50-day average (-29.68%), RSI 45 — neutral momentum, with a 3-month return of -30.29%.
Valuation & quality: Vitrafy Life Sciences Limited trades on forward P/E -9.3, price-to-book 4.48; fundamentals show net margin 0.0%, return on equity -46.3%.
Analyst consensus: 3 analysts have a mean 12-month price target of A$5.06 (+110.1% vs the last close; range A$5.03 – A$5.13), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Clinical and regulatory progress could unlock commercial partnerships and improve investor sentiment.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +1.80% | +27.20% | +17.70% | +16.20% | +16.30% | +10.00% | +3.90% | -39.00% |
Fundamentals
Analyst price target
Technical signals
About Vitrafy Life Sciences Limited
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions.
Sector: Technology · Industry: Software - Infrastructure · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.